Dipharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Dipharma is a third-generation, family-owned Italian CDMO and API manufacturer with over 75 years of experience. The company provides exclusive synthesis services and a catalog of APIs for the generic market, leveraging a strong foundation in handling hazardous chemistry and a global operational footprint. With a workforce of approximately 600, Dipharma emphasizes quality, safety, and innovation, positioning itself as a trusted, financially stable partner for pharmaceutical companies worldwide.

Generic Drugs

Technology Platform

Expertise in chemical process development and manufacturing, particularly for complex and hazardous chemistries. Capabilities include process development, scale-up, a broad range of chemical technologies, cGMP manufacturing, quality systems (Six Sigma, Lean), and IP support.

Opportunities

The growing trend of pharmaceutical outsourcing and demand for reliable API suppliers, especially for complex chemistry, presents a significant opportunity.

Expansion in key markets like the US and China through its local offices can drive further growth.

Risk Factors

Key risks include dependency on client projects and potential revenue volatility, intense regulatory scrutiny and compliance risks across multiple geographies, and strong competition in the global CDMO and API manufacturing market.

Competitive Landscape

Dipharma competes in the global CDMO and generic API market against large multinational firms (e.g., Lonza, Catalent) and low-cost producers, particularly in Asia. It differentiates through specialized expertise in hazardous chemistry, a family-owned long-term focus, and a multi-site European manufacturing base.

More companies in Small Molecule Drugs →More companies in Italy →